Novartis’ Kisqali hits endpoints in Phase III breast cancer trial
Kisqali is the only CDK4/6 inhibitor to show superior overall survival in advanced breast cancer.
Read More
Tag: CDK4/6 inhibitor
Kisqali wins speedy US breast cancer nod
Novartis’ Kisqali has been approved for breast cancer in the US less than one month after being filed with the US Food and Drug Administration.
Read More
EU, US approvals for Faslodex combinations
AstraZeneca’s Faslodex has been cleared on both sides of the Atlantic for use in combination with a CDK4/6 inhibitor.
Read More
US nod for Novartis’ breast cancer drug Kisqali
Novartis’ selective cyclin-dependent kinase inhibitor Kisqali has been approved by the US Food and Drug Administration as a treatment for patients with a certain form of breast cancer.
Read More
- Kahimmune Therapeutics enters licensing agreement with Gustave Roussy and SATT Paris-Saclay
- IBSA UK&I launches Perovial for the treatment of acute Peyronie’s disease
- En Carta Diagnostics’ EC Pocket Lyme test receives FDA Breakthrough Device Designation
- ALK’s EURneffy receives positive CHMP opinion for emergency anaphylaxis treatment in children
- CERo reports encouraging early data from phase 1 trial of CER‑1236
